Canada Imports Chinese Cancer Drug Amid Shortage

Health Canada has authorized the exceptional importation and sale of a Chinese-authorized version of the chemotherapy drug Ifosfamide to address a critical shortage. This injectable medication is essential for treating specific cancers, including soft tissue sarcoma, pancreatic, and cervical cancers, though some Ontario and Quebec hospitals have noted they are not currently using it. This regulatory move is notable as it's the first instance of Health Canada allowing a Chinese-authorized drug to be imported and sold to alleviate a severe drug shortage. The authorized Chinese product shares the same active ingredient, strength, dosage form, and administration route as the Canadian-authorized version. This situation comes as the European Medicines Agency also reported an ongoing shortage of Ifosfamide-containing medicines, expected to persist until early 2027. Pharmaceutical policy expert Mina Tadrous highlighted that while China is a major source of pharmaceutical ingredients, importing a product specifically intended for the Chinese market is unique. Health Canada has implemented a rigorous testing process to ensure the imported drug meets Canadian standards, including necessary labeling adjustments and specific storage instructions, to minimize risks to patients.